3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 2
1
Status
Recruiting
12
Active not recruiting
5
Not yet recruiting
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Conditions
Lymphoma, Follicular
1
Lymphoma, B-Cell
1
Interventions
Specimen Handling
22
Magnetic Resonance Spectroscopy
20
Carboplatin
17
Gemcitabine
15
pembrolizumab
13
Cisplatin
13
Paclitaxel
12
Injections
11
Interviews as Topic
10
fludarabine
9
Radiotherapy
9
Cyclophosphamide
9
Oxaliplatin
8
Dexamethasone
8
Biopsy
8
Bevacizumab
8
toripalimab
7
Nivolumab
7
Irinotecan
7
Fluorouracil
7
Bortezomib
7
X-Rays
6
Radiosurgery
6
Pemetrexed
6
Leucovorin
6
Capecitabine
6
durvalumab
5
cemiplimab
5
anlotinib
5
Doxorubicin
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Bendamustine Hydrochloride
×
30 days
×
Clear all
NCT07634471
2026-06-08
MK-1045-007
Merck Sharp & Dohme LLC
Phase 2/3
Not yet recruiting
960 enrolled
NCT07593482
2026-05-18
FC-BALANCE
Swiss Cancer Institute
Phase 2
Not yet recruiting
92 enrolled